Bio-Techne Corporation (TECH) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Bio-Techne Corporation
Address
614 McKinley Place N.E.
Minneapolis, MN 55413
United States of America (the)
Phone
612 379 8854
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3000
First IPO Date
February 09, 1989
Key Executives
| Name | Title | Pay | Year Born |
| Kim Kelderman | Chief Executive Officer, President & Director | 2.29M | 1968 |
| Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | 835,661 | 1975 |
| William A. Geist | President of Protein Sciences Segment | 1.34M | 1969 |
| James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | 1.67M | 1971 |
| Steve Crouse | President of Diagnostics & Spatial Biology Segment | 0 | 1973 |
| Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
| Gerry Andros | Vice President of Sales and Marketing | 0 | N/A |
| Luca Cicchetti | Managing Director | 0 | N/A |
| Martin Wirtz | Senior Vice President of Strategy & Corporate Development | 0 | N/A |
| David Clair | Vice President of Investor Relations | 0 | N/A |
| Gary J. Latham | Vice President & Chief Technology Officer | 0 | N/A |
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.